Cancer Research Technology | GenomeWeb

Cancer Research Technology

The new firm, created by Syncona and Cancer Research Technology, has raised $17.5 million to support development of individualized therapies targeted to tumor neoantigens.

Biomérieux has been awarded US Patent No. 8,106,172, "Nucleic acid sequences that can be used as primers and probes in the amplification and detection of SARS coronavirus."

In its companion diagnostics development program for an investigational PARP inhibitor oncologic, Pfizer is pursuing methylation-specific biomarkers rather than BRCA gene mutations to help personalize the drug.

MDxHealth will use its DNA methylation platform to identify and develop biomarkers that can predict patient response to a PARP inhibitor under development by Newcastle University, Cancer Research Technology, and Pfizer.

AstraZeneca and Cancer Research UK will contribute a combined £5.6 million ($8.9 million) to the Institute of Cancer Research to discover and develop cancer drugs that target molecular chaperones. AstraZeneca will have an exclusive worldwide license to compounds developed during the collaboration.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.